CAS186028-79-5 Chemicals pink BK EBDP BK 3,4-methylenedioxy-N-methylcathinone MDMC empathogen

 
bk-MDMC /BK-EBDP (Crystals)
 

Specifications

Dibutylone also known as bk-DMBDB with the IUPAC name being 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one.
 
The molecular formula is C13H17NO3 with formula weight of 271.7, a molecular weight of 235.28, a monoisotopic mass of 235.120843 and is a crystalline solid with a purity of ≥98%. The chemical should be stored at -20°C which will give allow the chemical to stay stable and have a life span of two years. The CAS number is 802286-83-5.
 
According to Cayman Chemical research the product is a crystalline solid that can be dissolved in a variety of solvents. It is usually dissolved in organic solvents such as dimethyl formamide, ethanol, and DMSO and should always be purged with an inert gas. The solubility found in ethanol is 0.3, DMSO is 10, and Dimethyl formamide is 5 mg/ml.
 
Dibutylone is still being researched and is considered a research compound. At this time it is only intended for scientific research and forensic settings and is NOT for human consumption.
 

bk was first made in 1912. It was used to improve psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. BKMDMA is commonly associated with dance parties, raves, and electronic dance music. It is often sold mixed with other substances such as ephedrine,amphetamine, and methamphetamine.
In 2014, between 9 and 29 million people between the ages of 15 and 64 used ecstasy (0.2% to 0.6% of the world population). This was broadly similar to the percentage of people who use cocaine, amphetamines, and opioids, but fewer than forcannabis. In the United States, about 0.9 million people used ecstasy in 2010.
Bk is generally illegal in most countries. Limited exceptions are sometimes made for research.Researchers are investigating whether a few low doses of MDMA may assist in treating severe, treatment-resistant posttraumatic stress disorder (PTSD). In November 2016, phase 3 clinical trials for PTSD were approved by the United States Food and Drug Administration to assess effectiveness and safety.